Disease Landscape and Forecast Insights

Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands; the disease may occur alone (primary SS) or…

The wet age-related macular degeneration (AMD) therapy market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, Novartis’…

Hormone receptor (HR)-positive / HER2-negative breast cancer has the highest incidence of all breast cancer subtypes. Treatment decisions are influenced by the stage of the disease, the patient’s…

The multiple sclerosis (MS) therapy market continues to evolve, with each new FDA-approved disease-modifying therapy (DMT) further expanding treatment choices. The newest entrants (e.g., Zeposia,…

Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. Treatments are needed that can…

Idiopathic pulmonary fibrosis (IPF), one of the most common interstitial lung diseases, is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first…

Until recently, FDA-approved treatments for Alzheimer’s disease (AD) were limited to modestly effective symptomatic agents (e.g., donepezil, memantine), but in 2021, Biogen / Eisai’s Aduhelm (…

Metastatic esophageal cancer remains a subpopulation for which few treatment options exist. For decades, treatment was limited to chemotherapy-based regimens such as FOLFOX and DCF, but the recent…

Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. It is caused by a mutation in one hemoglobin beta (HBB) gene (beta thalassemia minor) or a…

Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the disease’s relatively high prevalence…

Triple-negative breast cancer is an aggressive disease with high unmet need. There has been a historical lack of targeted therapies, although the treatment landscape has evolved with the approval…

Major depressive disorder is a chronic drug-treated condition, and treatment of it is ingrained with generic therapies. However, many of these therapies suffer from shortcomings in efficacy and/or…